HW201877 is a potent and orally active 15-prostaglandin dehydrogenase (15-PGDH) inhibitor with an IC50 of 3.6 nM. HW201877 demonstrates robust cellular efficacy in elevating PGE2 levels in A549 cells and exhibits remarkable efficacy in animal models of tissue injury and fibrosis. HW201877 can be used for the study of inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and Crohn’s disease (CD).

(R)-SW033291 is the R-type enantiomer of SW033291. (R)-SW033291 is a potent and high-affinity inhibitor of 15-PGDH. (R)-SW033291 increases prostaglandin PGE2 levels in bone marrow and other tissues. (R)-SW033291 also promotes tissue regeneration.

MF-DH-300 is a 15-PGDH inhibitor with an IC50 of 1.6 nM. MF-DH-300 blocks binding of 15-PGDH to PGE2 and increases stem cell proliferation and muscle force, as well as improves mitochondrial function. MF-DH-300 increases survival motor neuron (SMN) protein expression. MF-DH-300 can be used for muscle disorders like spinal muscular atrophy (SMA) research.

SW222746 (SW 222746) is a potent selective, orally active inhibitor of 15-Prostaglandin dehydrogenase (15-PGDH) with IC50 of 3 nM.

SW033291 is a potent inhibitor of 15-PGDH enzyme with IC50 value of 1.5 nM and dissociation constant Ki app value of 0.1 nM.